Transplanterede patienter, der får immunosuppressiv behandling (f. eks. systemisk tacrolimus) har en øget risiko for at udvikle lymfomer, hvorfor patienter, der behandles med Protopic og udvikler lymphadenopati bør følges nøje for at sikre, at lymphadenopatien helbredes.
Transplant patients receiving immunosuppressive regimens (e. g. systemic tacrolimus) are at increased risk for developing lymphoma; therefore patients who receive Protopic and who develop lymphadenopathy should be monitored to ensure that the lymphadenopathy resolves.